

Genomic solutions for confident decisions

NeoGenomics offers a comprehensive genomic testing portfolio, integrating flexible sequencing platforms, multiomics options, advanced data analysis, and large-scale, real-world oncology data to optimize your therapeutic development.



Trial Enrollment (inclusion/exclusion)	Patient stratification	Liquid biopsy	Molecular residual disease (MRD)
Biomarker profiling	Biomarker identification and validation	Gene expression	Genetic variations affecting drug targets, drug metabolism
Genotyping	Novel drug targets	Cytogenetics	Others

With CAP-accreditation and CLIA-certification, our labs ensure the highest quality through validated assays and customized solutions aligned to your program. Get in touch to learn about our custom solution offerings.

Genomic Assays

NGS
IgH Clonality and MRD
323 Gene Panel (solid tumor)
Brain NGS Fusion Panel
BRCA1/2 Mutation Analysis
Breast NGS Fusion Panel
Cholangio/Pancreatic Carcinoma NGS Fusion Panel
Colorectal NGS Fusion Panel
Ewing Sarcoma NGS Fusion Panel
Human Comprehensive Cancer Panel (275 gene)
Lung Complete NGS Fusion Panel
Lung NGS Fusion Panel
Neo Comprehensive® – Heme Cancers Panel
Neo RaDaR® ST (solid tumor MRD)
Non-Ewing Sarcoma NGS Fusion Panel
NTRK & RET NGS Fusion Panel

NGS (cont.)
NTRK NGS Fusion Panel
Oncomine Myeloid Panel
Prostate NGS Fusion Panel
RNAseq Exome
RNAseq Transcriptome
Salivary Gland NGS Fusion Panel
Sarcoma Comprehensive NGS Fusion Panel
Thyroid NGS Fusion Panel
TruSight™ Oncology 500 ctDNA v2
TruSight™ Oncology 500 HT
Universal Solid Tumor NGS Fusion Panel
Whole Exome Sequencing (WES)
Whole Genome Sequencing (WGS)
Whole Transcriptome Sequencing (WTS)

Additional validation activities may be required depending on the intended use of the assay. Availability is subject to change. For a current listing, please contact a NeoGenomics representative.

Genomic Assays

Fragment Analysis	Sanger Sequencing
B-Cell Gene Rearrangement Analysis	ABL1 Kinase Domain Mutation Analysis
Calreticulin (CALR) Mutation Analysis	BTK Inhibitor Acquired Resistance Panel
CEBPA Mutation Analysis	CSF3R Mutation Analysis
FLT3 Mutation Analysis	CXCR4 Mutation Analysis
FLT3-TKD, NPM1 Analysis	IgVH Mutation Analysis
HPV DNA Tissue Test	JAK2 Exon 12-13 Mutation Analysis
Microsatellite Instability (MSI) Analysis	JAK2 V617F Mutation Analysis (qualitative)
NPM1 MRD Analysis	KIT (c-KIT) Mutation Analysis
NPM1 Mutation Analysis	MPL Mutation Analysis
T-Cell Receptor Beta Gene Rearrangement Analysis	MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL
T-Cell Receptor Gamma Gene Rearrangement Analysis	MYD88 Mutation Analysis
PCR	NanoString nCounter®
BCR-ABL1 Analysis	ADC Development Panel
BRAF Mutation Analysis	Breast Cancer 360 Panel
EGFR Mutation Analysis	Immune Pathways + Tumor Signaling Panels (Multiomics)
IDH1/IDH2 Mutation Analysis	Lymphoma Subtyping (LST) Test
inv(16), CBFβ-MYH11 Translocation Analysis	Metabolic Pathways Panel
JAK2 V617F Mutation Analysis (quantitative)	PanCancer Immune Profiling Panel
KRAS Mutation Analysis	PanCancer IO 360™ Panel
MET Exon 14 Deletion Analysis	PanCancer Pathways Panel
MGMT Gene Promoter Methylation Analysis	Tumor Signaling 360 Panel
MLH1 Promoter Methylation Analysis	
PML-RARA Translocation t(15;17) Analysis	

Additional validation activities may be required depending on the intended use of the assay. Availability is subject to change. For a current listing, please contact a NeoGenomics representative.

To learn more about **NeoGenomics Pharma Services**, visit us online at [NeoGenomics.com/Partners](https://www.NeoGenomics.com/Partners), call us at 866.776.5907, option 3, or email us at ContactPharma@NeoGenomics.com.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phn: 866.776.5907
Fax: 239.690.4237

[NeoGenomics.com](https://www.NeoGenomics.com)
All trademarks are the property of their respective owners.
CORP-MRKT-0377 03.26